India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
The ICC U19 Women’s T20 World Cup 2027 is set to commence on January 21,…
Iodine Deficiency Day or World Iodine Deficiency Disorders Prevention Day is celebrated on October 21…
There is an imported case of the Bundibugyo strain of the Ebola virus in the…
On October 21, 2026, the Drugs Controller General of India (DCGI) approved Zytorvi (toripalimab) in…
India was ranked third in the Ipsos Quality of Care Perception Index 2026 after Malaysia…
Jamnagar is a coastal city in the state of the Gujarat and it is emerging…